Houlbrook S, Harris A L, Carmichael J, Stratford I J
Molecular Oncology Laboratories, Imperial Cancer Research Fund, John Radcliffe Hospital, Oxford, U.K.
Anticancer Res. 1996 Jul-Aug;16(4A):1603-10.
Topoisomerase II is a key target of many anticancer drugs used to treat lung cancer. We measured the expression of topoisomerase II alpha and beta mRNA's and also the levels of cellular topoisomerase II alpha and beta protein and concluded that topoisomerase II alpha levels are important in cellular resistance to the topoisomerase II inhibitors examined. This can be clearly seen in pairs of matched cell lines. However, when looking at a panel of cell lines with a range of histological types the importance of the enzyme can be masked by other cellular characteristics such as repair and detoxification mechanisms.
拓扑异构酶II是用于治疗肺癌的许多抗癌药物的关键靶点。我们测量了拓扑异构酶IIα和β mRNA的表达以及细胞拓扑异构酶IIα和β蛋白的水平,并得出结论,拓扑异构酶IIα水平在细胞对所检测的拓扑异构酶II抑制剂的抗性中很重要。这在配对的匹配细胞系中可以清楚地看到。然而,当观察一组具有一系列组织学类型的细胞系时,该酶的重要性可能会被其他细胞特征(如修复和解毒机制)所掩盖。